Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Act of 1934
Clearmind Medicine Inc.
(Name of Issuer)
Common Shares, no par value
(Title of Class of Securities)
1850532047
(CUSIP Number)
November 17, 2022
(Date of event which requires filing of this statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ☐ | Rule 13d-1(b) | |
| ☒ | Rule 13d-1(c) | |
| ☐ | Rule 13d-1(d) |
| * | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| 1 | NAME OF REPORTING PERSON
SciSparc Ltd. |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒ |
| 3 | SEC USE ONLY
|
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Israel |
NUMBER
OF |
5 | SOLE VOTING POWER
230,769(1) |
|
| 6 | SHARED VOTING POWER
0 |
||
| 7 | SOLE DISPOSITIVE POWER
230,769 (1) |
||
| 8 | SHARED DISPOSITIVE POWER
0 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
230,769(1) | |
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ☐
|
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.33% (2) | |
| 12 | TYPE OF REPORTING PERSON
CO | |
| (1) | Consists of 230,769 Common Shares of the issuer held directly by SciSparc Ltd. |
| (2) | Based on 2,473,617 Common Shares issued and outstanding as of November 16, 2022, based on information received from the Issuer. |
2
Item 1(a) Name of Issuer:
Clearmind Medicine Inc. (the “Issuer”)
Item 1(b) Address of Issuer’s Principal Executive Offices:
101 – 1220 West 6th Avenue, Vancouver, British Columbia, Canada
Item 2(a) Name of Person Filing:
SciSparc Ltd.
Item 2(b) Address or Principal Business Office or, if none, Residence:
20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916 Israel
Item 2(c) Citizenship:
Israel
Item 2(d) Title of Class of Securi ties:
Common Share, no par value
Item 2(e) CUSIP Number:
1850532047
Item 3 If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is:
Not applicable.
Item 4 Ownership.
See items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which is incorporated herein.
Item 5 Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐
Item 6 Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not applicable.
Item 8 Identification and Classification of Members of the Group.
Not applicable.
Item 9 Notice of Dissolution of Group.
Not applicable.
Item 10 Certifications.
Not applicable.
3
SIGNATURES
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| Dated: December 13, 2022 | SCISPARC LTD. | |
| By: | /s/ Oz Adler | |
| Name: | Oz Adler | |
| Title: | Chief Executive Officer & Chief Financial Officer | |
4